Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryCongestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementA Review of the External Validity of Clinical Trials with Beta-Blockers in Heart FailureReducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education ProgramDiabetic cardiomyopathy: pathophysiology and clinical featuresIndividual patient data meta-analysis of beta-blockers in heart failure: rationale and designSources of evidence for systematic reviews of interventions in diabetes.Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004.Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research DatabaseUtilization of evidence-based treatment in elderly patients with chronic heart failure: using Korean Health Insurance claims database.Bucindolol: a pharmacogenomic perspective on its use in chronic heart failureGlucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure.Association between higher rates of cardioprotective drug use and survival in patients on dialysisBeta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control.Effectiveness comparison of cardio-selective to non-selective β-blockers and their association with mortality and morbidity in end-stage renal disease: a retrospective cohort study.Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure.Management of patients with type 2 diabetes after acute coronary syndromes.Beta and angiotensin blockades are associated with improved 10-year survival in renal transplant recipients.Metabolic dysfunction in diabetic cardiomyopathy.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsA critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus.Canadian Cardiovascular Society Consensus Conference guidelines on heart failure--2008 update: best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathiesType 2 diabetes mellitus and heart failure.Diabetes, left ventricular systolic dysfunction, and chronic heart failure.High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2 -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts.Diabetes mellitus and the heart.Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.The Real Role of β-Blockers in Daily Cardiovascular Therapy.Carvedilol and antioxidant proteins in a type I diabetes animal model.Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells.Do patients with heart failure appropriately undergo invasive procedures post-myocardial infarction? Results from a prospective multicentre study.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology.Inhibiting Insulin-Mediated β2-Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction.Diabetes: prevention of cardiovascular events.Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat.[A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy].
P2860
Q22241786-97D6E79C-532A-427B-9B96-018800BACCE1Q27003819-8B3510D0-D8DE-4801-BF58-2944C7CF3F97Q28068618-1918FC2B-FD1F-4930-A172-2A2C13FEBDF1Q28201111-CBCAAC8B-3C7E-49BE-BE1D-781C9869626DQ30457504-BB13A251-8804-4A4B-BC17-8F6814F7BD2DQ30534526-EE2D89A6-9B11-4817-91B6-B6177A26CC84Q33223698-311F1EF9-7CFC-4839-A6BE-7EE525E30384Q33638261-0DFE4052-02F0-49F4-8EB2-A9EDD074ADA4Q33873040-4487B320-09F0-48C8-A8B6-690112DDDB1AQ34360297-68495A0D-1C70-4559-A23D-60A6B8B88287Q35117742-4EA9F90B-DDA0-4F95-9377-819D3B069E16Q35772087-8C617832-0FEE-4ADC-A98A-20E3E99BAF1AQ35812557-5C73EBD3-2548-4DF2-8C4E-C2C9711B44D9Q35818321-6865D6A3-B7A7-410C-98AA-E1DEFDA341CBQ35969769-48A2485A-1590-4C08-8799-0FBE5F8F3FA8Q35984038-86BB28B6-A992-4D05-8779-BB6AEFA441D7Q36013015-37AF006C-0FE7-46A1-8798-5C86F4E714DAQ36333931-57E001C7-64E7-4352-AF9A-6B33AB81AC4BQ36701855-B31CF952-9E79-4B06-AD85-5172CF3AF8EAQ36930481-C29BEE0B-AEF0-48B4-8520-03A82CE0CFFBQ37011769-96881033-0D19-405D-973D-3C53A11FC21AQ37031357-7C03067A-5FEB-4A3B-8A3C-2A2763303A41Q37061992-8C559240-55D8-490C-99F3-052B83016B86Q37069176-5F35ECC5-3E4F-485D-B36C-08A91AA4B622Q37143034-C67BCBF1-D9C4-4F79-BC42-7CD06844EC7CQ37700020-F468870C-A34E-41AB-9BAF-D012266C547DQ38018724-D14BA9E5-8340-433B-9996-251848D3C418Q38604382-57F6BF33-D284-4A8D-89A7-2869535C4E16Q38978490-38C145E2-07DB-435A-BD96-55C6DD5EAAD5Q39208428-3DF8C464-0B65-4DC4-BA3B-67EA059FD2A6Q39224330-129CE275-84BD-47E9-936A-7BDD790A5B0CQ39360754-599857E0-95CB-4638-86EE-CAD7CDC6492DQ40105240-D78D254E-7D6E-4340-AD65-A62098DE0CFDQ41686228-E102FD33-BA41-4B3F-BD3F-01074FE55707Q41969432-3410AF9E-BDE5-4074-8FFB-8FD97A72D872Q44916704-59CA07FE-3DEC-4ED5-AD46-CDA58E28216EQ46138106-5EE74783-91C8-4EBB-A91E-98B2D51F4C5DQ46721557-0E6D5794-8F95-413B-84DA-DB4C08F2C8AEQ46802160-F01499B1-9763-4486-9B75-5B93F3C3B8CDQ46893154-78363F66-B7F6-4CC0-9343-7DFC7AD5CAF8
P2860
Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@ast
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@en
type
label
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@ast
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@en
prefLabel
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@ast
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@en
P2093
P1476
Are beta-blockers as efficacio ...... f large-scale clinical trials.
@en
P2093
Richard E Gilbert
Steven Joseph Haas
P304
P356
10.1016/S0002-8703(03)00403-4
P407
P50
P577
2003-11-01T00:00:00Z